Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.56), $0.71 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $188.8 million versus the consensus estimate of $206.44 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.